Do analysts recommend PASG or RNAZ?

Passage Bio presently has a consensus target price of $13.25, indicating a potential upside of 173.20%. Given Passage Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Passage Bio is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11 TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, PASG or RNAZ?

Passage Bio is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A TransCode Therapeutics N/A N/A -$34.66M -$50.33 N/A

Is PASG or RNAZ more profitable?

Passage Bio's return on equity of -150.88% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% TransCode Therapeutics N/A -875.35% -50.36%

Do analysts recommend RNAZ or SNSE?

Sensei Biotherapeutics has a consensus price target of $48.00, suggesting a potential upside of 239.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sensei Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Which has preferable valuation and earnings, RNAZ or SNSE?

TransCode Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$50.33 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Is RNAZ or SNSE more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -50.36% Sensei Biotherapeutics N/A -83.59% -256.50%

Do analysts prefer RNAZ or TPST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation and earnings, RNAZ or TPST?

Tempest Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$50.33 N/A Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A

Is RNAZ or TPST more profitable?

Tempest Therapeutics' return on equity of -355.61% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -50.36% Tempest Therapeutics N/A -355.61% -121.21%

Do analysts prefer RNAZ or NCEL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, RNAZ or NCEL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$50.33 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is RNAZ or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -50.36% NLS Pharmaceutics N/A N/A N/A

Do analysts prefer RNAZ or XCUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is RNAZ or XCUR more profitable?

Exicure's return on equity of -179.41% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -50.36% Exicure N/A -179.41% -64.37%

TransCode Therapeutics (RNAZ) Competitors

$5.24 +0.27 (+5.43%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$5.18 -0.06 (-1.15%)

As of 06/29/2026 04:10 PM Eastern

Compare

RNAZ vs. PASG, SNSE, TPST, NCEL, and XCUR

Should you buy TransCode Therapeutics stock or one of its competitors? MarketBeat compares TransCode Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TransCode Therapeutics include Passage Bio (PASG), Sensei Biotherapeutics (SNSE), Tempest Therapeutics (TPST), NLS Pharmaceutics (NCEL), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry.

How does TransCode Therapeutics compare to Passage Bio?

Passage Bio (NASDAQ:PASG) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Passage Bio is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A

In the previous week, Passage Bio had 5 more articles in the media than TransCode Therapeutics. MarketBeat recorded 7 mentions for Passage Bio and 2 mentions for TransCode Therapeutics. Passage Bio's average media sentiment score of 0.45 beat TransCode Therapeutics' score of 0.44 indicating that Passage Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Passage Bio	Neutral
TransCode Therapeutics	Neutral

Passage Bio has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

53.5% of Passage Bio shares are held by institutional investors. 4.9% of Passage Bio shares are held by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Passage Bio's return on equity of -150.88% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
TransCode Therapeutics	N/A	-875.35%	-50.36%

Passage Bio presently has a consensus target price of $13.25, indicating a potential upside of 173.20%. Given Passage Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Passage Bio is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Passage Bio beats TransCode Therapeutics on 10 of the 13 factors compared between the two stocks.

How does TransCode Therapeutics compare to Sensei Biotherapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Sensei Biotherapeutics has a consensus price target of $48.00, suggesting a potential upside of 239.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sensei Biotherapeutics is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Sensei Biotherapeutics' return on equity of -83.59% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-50.36%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

10.5% of Sensei Biotherapeutics shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

TransCode Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

In the previous week, TransCode Therapeutics had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 2 mentions for TransCode Therapeutics and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.93 beat TransCode Therapeutics' score of 0.44 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
TransCode Therapeutics	Neutral
Sensei Biotherapeutics	Positive

TransCode Therapeutics has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

Summary

Sensei Biotherapeutics beats TransCode Therapeutics on 9 of the 13 factors compared between the two stocks.

How does TransCode Therapeutics compare to Tempest Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

In the previous week, TransCode Therapeutics and TransCode Therapeutics both had 2 articles in the media. Tempest Therapeutics' average media sentiment score of 1.43 beat TransCode Therapeutics' score of 0.44 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
TransCode Therapeutics	Neutral
Tempest Therapeutics	Positive

Tempest Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

22.5% of Tempest Therapeutics shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by company insiders. Comparatively, 36.3% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TransCode Therapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, indicating that its share price is 285% less volatile than the broader market.

Tempest Therapeutics' return on equity of -355.61% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-50.36%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Summary

Tempest Therapeutics beats TransCode Therapeutics on 7 of the 10 factors compared between the two stocks.

How does TransCode Therapeutics compare to NLS Pharmaceutics?

TransCode Therapeutics (NASDAQ:RNAZ) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

NLS Pharmaceutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-50.36%
NLS Pharmaceutics	N/A	N/A	N/A

In the previous week, TransCode Therapeutics had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 2 mentions for TransCode Therapeutics and 1 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.89 beat TransCode Therapeutics' score of 0.44 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.

Company	Overall Sentiment
TransCode Therapeutics	Neutral
NLS Pharmaceutics	Very Positive

TransCode Therapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NLS Pharmaceutics beats TransCode Therapeutics on 4 of the 6 factors compared between the two stocks.

How does TransCode Therapeutics compare to Exicure?

TransCode Therapeutics (NASDAQ:RNAZ) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

42.8% of Exicure shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by insiders. Comparatively, 52.8% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

TransCode Therapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, Exicure has a beta of 3.53, indicating that its stock price is 253% more volatile than the broader market.

Exicure's return on equity of -179.41% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-50.36%
Exicure	N/A	-179.41%	-64.37%

Exicure has higher revenue and earnings than TransCode Therapeutics. Exicure is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A
Exicure	$500K	28.03	-$4.95M	-$1.55	N/A

In the previous week, TransCode Therapeutics had 1 more articles in the media than Exicure. MarketBeat recorded 2 mentions for TransCode Therapeutics and 1 mentions for Exicure. Exicure's average media sentiment score of 1.89 beat TransCode Therapeutics' score of 0.44 indicating that Exicure is being referred to more favorably in the news media.

Company	Overall Sentiment
TransCode Therapeutics	Neutral
Exicure	Very Positive

Summary

Exicure beats TransCode Therapeutics on 8 of the 11 factors compared between the two stocks.

Get TransCode Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNAZ vs. The Competition

Export

Metric	TransCode Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.72M	$3.04B	$6.85B	$12.20B
Dividend Yield	N/A	1.87%	2.66%	6.22%
P/E Ratio	-0.10	19.67	26.04	24.36
Price / Sales	N/A	338.22	550.14	102.43
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	0.46	4.25	10.98	6.49
Net Income	-$34.66M	$64.45M	$3.57B	$336.61M
7 Day Performance	7.82%	3.73%	2.60%	1.25%
1 Month Performance	1.95%	4.01%	0.93%	0.24%
1 Year Performance	-32.82%	34.35%	36.40%	30.16%

TransCode Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNAZ TransCode Therapeutics	0.2741 of 5 stars	$5.24 +5.4%	N/A	-34.3%	$4.72M	N/A	N/A	9	Short Interest Increase Gap Down
PASG Passage Bio	4.5213 of 5 stars	$6.05 -1.1%	$13.25 +119.0%	-26.8%	$19.42M	N/A	N/A	130	Insider Trade Gap Down
SNSE Sensei Biotherapeutics	3.7299 of 5 stars	$14.15 +2.1%	$48.00 +239.3%	+64.3%	$18.98M	N/A	N/A	40	Gap Up High Trading Volume
TPST Tempest Therapeutics	1.9346 of 5 stars	$1.27 +1.1%	N/A	-84.1%	$18.81M	N/A	N/A	20	Positive News Short Interest Decrease
NCEL NLS Pharmaceutics	1.5452 of 5 stars	$3.48 -1.7%	N/A	-86.8%	$18.60M	N/A	N/A	6	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNAZ) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransCode Therapeutics (RNAZ) Competitors

RNAZ vs. PASG, SNSE, TPST, NCEL, and XCUR

How does TransCode Therapeutics compare to Passage Bio?

Summary

How does TransCode Therapeutics compare to Sensei Biotherapeutics?

Summary

How does TransCode Therapeutics compare to Tempest Therapeutics?

Summary

How does TransCode Therapeutics compare to NLS Pharmaceutics?

Summary

How does TransCode Therapeutics compare to Exicure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ vs. The Competition

TransCode Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TransCode Therapeutics (RNAZ) Competitors

RNAZ vs. PASG, SNSE, TPST, NCEL, and XCUR

How does TransCode Therapeutics compare to Passage Bio?

Which has higher valuation and earnings, PASG or RNAZ?

Does the media favor PASG or RNAZ?

Which has more risk & volatility, PASG or RNAZ?

Do insiders & institutionals believe in PASG or RNAZ?

Is PASG or RNAZ more profitable?

Do analysts recommend PASG or RNAZ?

Summary

How does TransCode Therapeutics compare to Sensei Biotherapeutics?

Do analysts recommend RNAZ or SNSE?

Is RNAZ or SNSE more profitable?

Do institutionals and insiders have more ownership in RNAZ or SNSE?

Which has preferable valuation and earnings, RNAZ or SNSE?

Does the media prefer RNAZ or SNSE?

Which has more risk & volatility, RNAZ or SNSE?

Summary

How does TransCode Therapeutics compare to Tempest Therapeutics?

Does the media refer more to RNAZ or TPST?

Which has stronger valuation and earnings, RNAZ or TPST?

Do analysts prefer RNAZ or TPST?

Do institutionals and insiders hold more shares of RNAZ or TPST?

Which has more volatility and risk, RNAZ or TPST?

Is RNAZ or TPST more profitable?

Summary

How does TransCode Therapeutics compare to NLS Pharmaceutics?

Which has better valuation and earnings, RNAZ or NCEL?

Is RNAZ or NCEL more profitable?

Does the media favor RNAZ or NCEL?

Which has more volatility & risk, RNAZ or NCEL?

Do analysts prefer RNAZ or NCEL?

Summary

How does TransCode Therapeutics compare to Exicure?

Do analysts prefer RNAZ or XCUR?

Do institutionals and insiders have more ownership in RNAZ or XCUR?

Which has more volatility and risk, RNAZ or XCUR?

Is RNAZ or XCUR more profitable?

Which has preferable earnings & valuation, RNAZ or XCUR?

Does the media refer more to RNAZ or XCUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ vs. The Competition

TransCode Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools